Relationship between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prescribing and delirium in the ICU-A secondary analysis

被引:1
|
作者
Mulkey, Malissa A. [1 ]
Khan, Sikandar [2 ,3 ,4 ,5 ]
Perkins, Anthony [3 ,6 ]
Gao, Sujuan [3 ,6 ]
Wang, Sophia [3 ,7 ]
Campbell, Noll [4 ,5 ,8 ]
Khan, Babar [2 ,3 ,4 ,5 ]
机构
[1] Univ South Carolina, Coll Nursing, 1601 Greene St, Columbia, SC 29208 USA
[2] Indiana Univ Purdue Univ, Div Pulm Crit Care Sleep & Occupat Med, Indianapolis, IN USA
[3] Indiana Univ, Sch Med, Indianapolis, IN USA
[4] Indiana Univ, Ctr Aging Res, Indianapolis, IN USA
[5] Indiana Univ, Regenstrief Inst, Ctr Aging Res, Indianapolis, IN USA
[6] Indiana Univ Purdue Univ, Dept Biostat & Hlth Data Sci, Indianapolis, IN USA
[7] Dept Psychiat, Dept Biostat & Hlth Data Sci, Indianapolis, IN USA
[8] Purdue Univ, Dept Pharm Practice, Lafayette, IN USA
关键词
ACE inhibitor; angiotensin recepter blocker; critical care; delirium; intensive care; INTENSIVE-CARE-UNIT; CONFUSION ASSESSMENT METHOD; OLDER-ADULTS; RELIABILITY; VALIDITY; ASSOCIATION; SYSTEM;
D O I
10.1111/jgs.18285
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background: Studies suggest Angiotensin-Converting Enzyme inhibitors (ACEI) and Angiotensin Receptor Blockers (ARB) may slow the decline of memory function in individuals with mild to moderate Alzheimer's disease by regulating migroglial activation and oxidative stress within the brain's reticular activating system. Therefore, we evaluated the relationship between delirium prevalence and being prescribed ACEI and ARB in participants admitted to the intensive care units (ICU).Methods: A secondary analysis of data from two parallel pragmatic randomized controlled trials was performed. ACEI and ARB exposure was defined as being prescribed an ACEI or an ARB within six months prior to the ICU admission. The primary endpoint was the first positive delirium assessment based on Confusion Assessment Method for the ICU (CAM-ICU) for up to thirty days.Results: A total of 4791 patients admitted to the medical, surgical, and progressive ICU and screened for eligibility for the parent studies between February 2009 and January 2015 from two level 1 trauma and one safety net hospital in a large urban academic health system were included. Delirium rates in the ICU were not significantly different among participants with no exposure to ACEI/ARB (12.6%), or exposure to ACEI (14.4%), ARB (11.8%), or ACEI and ARB in combination (15.4%) in six months prior to the ICU admission. Exposure to ACEI (OR = 0.97[0.77, 1.22]), ARB (OR = 0.70 [0.47, 1.05]), or both (OR = 0.97 [0.33, 2.89]) in six months prior to ICU admission was not significantly associated with odds of delirium during the ICU admission after adjusting for age, gender, race, co-morbidities, and insurance status.Conclusions: While the impact of ACEI and ARB exposure prior to the ICU admission was not associated with the prevalence of delirium in this study, further research is needed to fully understand the impact of antihypertensive medications on delirium.
引用
收藏
页码:1873 / 1880
页数:8
相关论文
共 50 条
  • [11] Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review
    Mc Menamin, Una C.
    Murray, Liam J.
    Cantwell, Marie M.
    Hughes, Carmel M.
    CANCER CAUSES & CONTROL, 2012, 23 (02) : 221 - 230
  • [12] Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on accumulation of aliskiren in the kidney
    Rahman, Asadur
    Ohmori, Koji
    Kohno, Masakazu
    Nishiyama, Akira
    JOURNAL OF HYPERTENSION, 2013, 31 (04) : 659 - 660
  • [13] Cognitive enhancing effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on learning and memory
    Nade, V. S.
    Kawale, L. A.
    Valte, K. D.
    Shendye, N. V.
    INDIAN JOURNAL OF PHARMACOLOGY, 2015, 47 (03) : 263 - 269
  • [14] Angiotensin-converting Enzyme Inhibitors and Angiotensin Receptor Blockers as Potential Therapeutic Options for Pancreatic Cancer
    Asgharzadeh, Fereshteh
    Geraylow, Kiarash Roustai
    Khazaei, Majid
    Nassiri, Mohammadreza
    Hassanian, Seyed Mahdi
    Ferns, Gordon A.
    Avan, Amir
    CURRENT CANCER DRUG TARGETS, 2022, 22 (10) : 785 - 795
  • [15] Angiotensin receptor blockers, but not angiotensin-converting enzyme inhibitors, inhibit abnormal bone changes in spondyloarthritis
    Choi, Jin Sun
    Kim, Ji-Young
    Ahn, Min-Joo
    Jang, Hanbit
    Song, Seungtaek
    Choi, Sung Hoon
    Park, Ye-Soo
    Jo, Sungsin
    Kim, Tae-Hwan
    Shim, Seung Cheol
    EXPERIMENTAL AND MOLECULAR MEDICINE, 2023, 55 (11) : 2346 - 2356
  • [16] Efficacy and safety of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for IgA nephropathy in children
    Vaz de Castro, Pedro Alves Soares
    Bitencourt, Leticia
    Pereira, Bruno Wilnes Simas
    Lima, Ananda Queiroz Rocha
    Hermida, Henrique Santos
    Moreira Neto, Carlos Roberto
    Mestriner, Mariana Dinamarco
    Simoes e Silva, Ana Cristina
    PEDIATRIC NEPHROLOGY, 2022, 37 (03) : 499 - 508
  • [17] Aliskiren - an alternative to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in the therapy of arterial hypertension
    Zaporowska-Stachowiak, Iwona
    Hoffmann, Karolina
    Bryl, Wieslaw
    Minczykowski, Andrzej
    ARCHIVES OF MEDICAL SCIENCE, 2014, 10 (04) : 830 - 836
  • [18] Is angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy protective against prostate cancer?
    Mao, Yeqing
    Xu, Xin
    Wang, Xiao
    Zheng, Xiangyi
    Xie, Liping
    ONCOTARGET, 2016, 7 (06) : 6765 - 6773
  • [19] Complementary effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in slowing the progression of chronic kidney disease
    Ripley, Elizabeth
    AMERICAN HEART JOURNAL, 2009, 157 (06) : S7 - S16
  • [20] Perioperative management of angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers: a survey of perioperative medicine practitioners
    Walker, Sophie L. M.
    Abbott, Tom E. F.
    Brown, Katherine
    Pearse, Rupert M.
    Ackland, Gareth L.
    PEERJ, 2018, 6